Key takeaways
Ubrelvy (ubrogepant) and Zomig (zolmitriptan) are both medications used to treat migraine attacks in adults. However, they belong to different medication classes. Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor blocker, while Zomig is a triptan. Ubrelvy is taken orally and is available only as a brand-name medication, whereas Zomig is available in oral tablets, orally disintegrating tablets, and nasal spray forms, with both brand-name and generic options. Ubrelvy can be taken with or without food. Zomig should be taken at the first sign of a migraine, and its nasal spray form is suitable for those who have trouble swallowing pills. Common side effects of Ubrelvy include nausea, sleepiness, and dry mouth, while Zomig can cause dizziness, nausea, and chest pain. Ubrelvy interacts with many medications, including certain antibiotics and seizure medications, while Zomig can interact with medications that raise serotonin levels, increasing the risk of serotonin syndrome.
